Active comparators can reduce bias from treatment indication
In short: An article on pharmacoepidemiology methods explains that confounding by indication—when the clinical reason for prescribing a treatment also affects outcomes—threatens the validity of non-experimental studies on drug safety and effectiveness. It describes how choosing an active comparator, a treatment given for the same indication, can help control for this hard-to-measure bias.
Because the reason a drug is prescribed can itself be linked to how patients fare, isolating the drug's true effect in observational data is difficult. The article explains restricting study populations to patients sharing the same indication, including the active-comparator, new-user design, as a practical solution.
This is a conceptual discussion of methodology, not a study with new data of its own, so it offers guidance for future research design rather than new results.
Why it matters: Choosing a comparable 'active' treatment instead of no treatment can help researchers avoid misleading conclusions in real-world drug studies.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Research: Sendor and Sturmer (2022). Core concepts in pharmacoepidemiology: Confounding by indication and the role of active comparators. Pharmacoepidemiology and Drug Safety.
To cite this card, link to https://intellectplus.co.uk/app/science-research-using-active-comparators-to-reduce-bias-in-medical-effective.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Research methods · More in Science · Latest · A–Z · All topics